Valuation: Rezolute Inc

Market Cap 518M 453M 418M 387M 734M 49.42B 747M 5B 1.96B 24.3B 1.95B 1.9B 84.13B P/E 2026 *
-7.33x
P/E 2027 * -7.89x
Enterprise Value 518M 453M 418M 387M 734M 49.42B 747M 5B 1.96B 24.3B 1.95B 1.9B 84.13B EV / Sales 2026 *
-
EV / Sales 2027 * 225x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute Inc

Manager TitleAgeSince
Chief Executive Officer 58 2013-01-29
Director of Finance/CFO 52 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-14.41% - - 518M
-0.38%+0.40%+71.69%+128.83% 56.71B
+4.91%-3.30%+71.97%+92.14% 51.3B
+1.48%+10.52%+23.01%+495.47% 25.26B
-0.59%-1.00%-16.73%-12.99% 23.65B
+3.93%+7.11%+44.20%-1.96% 18.69B
+2.01%+7.22%+41.55%-24.93% 17.71B
-6.84%+4.81%+201.88%+348.11% 17.7B
-0.92%+8.90%+38.48% - 14.26B
+1.76%+5.82%+31.23%+195.70% 14.1B
Average +0.54%+3.45%+56.37%+152.55% 26.6B
Weighted average by Cap. +1.06%+2.16%+58.77%+145.18%

Financials

2026 *2027 *
Net sales - 2.3M 2.02M 1.86M 1.72M 3.26M 220M 3.32M 22.24M 8.72M 108M 8.65M 8.46M 374M
Net income -72.7M -63.61M -58.65M -54.25M -103M -6.93B -105M -702M -275M -3.41B -273M -267M -11.8B -75.12M -65.72M -60.6M -56.05M -106M -7.16B -108M -725M -284M -3.52B -282M -276M -12.2B
Net Debt - -
Logo Rezolute Inc
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-